Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors

Cell Biology International

Volumn 26, Issue 4, 2002, Pages 327-335

  Dyer, Kimberly D ^a   Linz Mcgillem, Laura A ^b   Alliegro, Mary Anne ^b   Alliegro, Mark C ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amiloride; Angiogenesis; Endothelial cell; uPA; Urokinase; Urokinase receptor; Urokinase type plasminogen activator

Indexed keywords

AMILORIDE; ANGIOGENESIS INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR WEIGHT; MORPHOGENESIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; SOLUBILITY;

EID: 0036349127     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbir.2001.0859     Document Type: Article

References (39)

1. Amiloride inhibition of angiogenesis in vitro
2. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model
3. Systemic amiloride inhibits experimentally induced neovascularization
4. Secretion of plasminogen activator from bovine parathyroid cells
5. Regulation of plasminogen activator in rat endometrial stromal cells: The role of epidermal growth factor
6. Amiloride inhibits phorbol ester-stimulated Na+/H+ exchange and protein kinase C. An amiloride analog selectively inhibits Na+/H+ exchange
7. Amiloride intercalates into DNA and inhibits DNA topoisomerase II
8. Macrophage fibrinolytic activity: Identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor
9. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation
10. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation
11. Amiloride directly inhibits growth factor receptor tyrosine kinase activity
12. Angiogenesis in rat aorta ring explant cultures
13. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors
14. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
15. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride
16. Growth stimulation of cultured endothelial cells by tumor cell homogenates
17. Bovine retinal explants cultured in collagen gels. A model system for the study of proliferative retinopathy
18. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1
19. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice
20. Capillary growth of rat aortic segments cultured in collagen gel without serum
21. Antimetastatic effect of amiloride in an animal tumour model
22. Amiloride and its analogs as tools in the study of ion transport
23. Binding of plasminogen to extracellular matrix
24. Amiloride is a cholinergic antagonist in the rabbit pancreas
25. Importance, localization and functional properties of the cell-associated form of plasminogen activator in mouse peritoneal macrophages
26. Plasminogen activators and angiogenesis
27. Tumor-promoting phorbol esters induce angiogenesis in vitro
28. Vascular outgrowths from tissue explants embedded in fibrin or collagen gels: A simple in vitro model of angiogenesis
29. Inhibition of mouse mastocytoma protein kinases by amiloride
30. Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer
31. Plasminogen activation and regulation of pericellular proteolysis
32. Cell-associated plasminogen activation: Regulation and physiological functions
33. Plasminogen activators in tissue remodeling and invasion: Mrna localization in mouse ovaries and implanting embryos
34. Differential protease expression by cutaneous squamous and basal cell carcinomas
35. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines
36. Amiloride selectively inhibits the urokinase-type plasminogen activator
37. Characterization of 125I-tissue plasminogen activator binding to cerebellar granule neurons
38. Selective inhibition of urokinase by substituted phenylguanidines: Quantitative structure-activity relationship analyses
39. Regulation of plasminogen activator in rat endometrial stromal cells: The role of prostaglandin E2